Guangxi LiuYao Group Co., Ltd: history, ownership, mission, how it works & makes money

From its founding in 1981 to the 1996 launch of online pharmacies and a 2015 push into third‑party logistics and e‑commerce, Guangxi LiuYao Group (603368.SS) has evolved into a regional powerhouse-ranked among China's top 50 pharmaceutical commercial enterprises by 2005-and in 2022 formally rebranded to reflect a modernization strategy; today the company is publicly listed with a market capitalization of about 6.98 billion CNY and an enterprise value near 9.24 billion CNY, trading on 389.06 million shares outstanding at a trailing P/E of 9.07 (EPS 1.98, forward P/E 9.04) while returning income via a 4.28% dividend yield (ex‑dividend May 29, 2025); operating a dual‑channel model that blends online ordering and home delivery with a network of physical stores, the group sources prescription and OTC medicines, medical devices and reagents, leverages third‑party logistics and tech investments for inventory and delivery efficiency, and generates revenue through wholesale/retail sales, e‑commerce transactions, logistics services and strategic partnerships-supported by analyst projections of roughly 4.5% annual revenue growth, 4.3% EPS CAGR and a projected return on equity of 10.1% within three years

Guangxi LiuYao Group Co., Ltd (603368.SS): Intro

• Founded in 1981 - entry into China's pharmaceutical distribution sector.
• 1996 - launched online pharmacy operations to extend retail reach.
• By 2005 - ranked among China's top 50 pharmaceutical commercial enterprises.
• 2015 - integrated third‑party pharmaceutical logistics and e‑commerce services.
• 2022 - rebranded from '广西柳州医药股份有限公司' to '广西柳药集团股份有限公司' to reflect broader group identity.
• 2025 - continues as a leading distributor in Guangxi with sustained national presence.

• 1981-1995: Established regional wholesale network across Guangxi, building relationships with domestic manufacturers and provincial hospitals.
• 1996-2004: Early mover in online pharmacy retailing; expanded retail network and digital ordering for institutional clients.
• 2005-2014: Scale-up phase; entered top‑50 national league of pharmaceutical commercial enterprises, standardized warehousing and regional logistics hubs.
• 2015-2021: Rollout of third‑party logistics (3PL) for pharmaceutical cold chain and regulatory‑compliant distribution; investments in e‑commerce B2C and B2B platforms.
• 2022-2025: Rebranding and group consolidation; focus on integrated supply‑chain solutions, cross‑border procurement for generics and continued expansion of retail pharmacy footprint.

• Wholesale distribution: procurement from manufacturers (domestic and select imports), inventory management, supply to hospitals, clinics and retail pharmacies.
• Retail & e‑commerce: brick‑and‑mortar pharmacies plus online pharmacy platforms for retail consumers and chronic medication refills.
• Third‑party logistics: warehousing (including cold chain), last‑mile delivery for pharmaceuticals and contract logistics for other players.
• Value‑added services: regulatory compliance support, drug traceability, tendering services for public hospitals and digital healthcare partnerships.

• Product margin on drug distribution (generics and branded): primary revenue driver - purchase cost vs. resale to institutions and retailers.
• Retail sales and online orders: higher margin on OTC and consumer healthcare products.
• Logistics & service fees: revenue from 3PL and supply‑chain services to third parties.
• Financial services & platform monetization (emerging): platform transaction fees, vendor services and data/analytics offerings.

• Listed entity: Shanghai Stock Exchange ticker 603368.SS.
• Typical shareholder mix (illustrative allocation as of 2025): largest state‑linked/group shareholder ~30%, institutional & public float ~50%, management and strategic partners ~20%.
• Governance: board with executive management drawn from logistics, pharma distribution and retail operations; regulatory compliance emphasis driven by pharmaceutical distribution licensing requirements.

• Distribution network: dozens of regional warehouses and hundreds of retail outlets across Guangxi and adjoining provinces.
• Cold‑chain capacity: dedicated refrigerated storage for temperature‑sensitive biologics and vaccines.
• e‑commerce penetration: online channel accounts for a growing share of retail sales (double‑digit CAGR since 2019 in online orders).
• Market position: among the leading pharmaceutical distributors in Guangxi by revenue and logistics footprint as of 2025.

• Strengthen integrated supply‑chain services and expand 3PL contracts with hospitals and manufacturers.
• Scale digital pharmacy services, improve medication adherence offerings and leverage data analytics.
• Selective geographic expansion beyond Guangxi and deeper partnerships with regional manufacturers.

Guangxi LiuYao Group Co., Ltd (603368.SS): History

• Founded: regional origins in Guangxi province (evolved through mergers and capacity expansion).
• Listed: Shanghai Stock Exchange under ticker 603368.SS.
• Core businesses: raw-material cultivation, processing, branded consumer products, and B2B ingredient supply.

• Investor profile: public float with institutional and retail participation; moderate valuation given P/E ~9 and steady EPS.
• Income for shareholders: 4.28% dividend yield with the noted ex-dividend date providing recurring cash returns.
• Enterprise valuation: EV/market-cap spread indicates leverage and operational scale across production and distribution.

Guangxi LiuYao Group Co., Ltd (603368.SS): Ownership Structure

• Mission: Provide comprehensive pharmaceutical products and services with a focus on accessibility, quality and operational efficiency.
• Channel strategy: Integrate physical pharmacies with online platforms to increase customer reach and convenience.
• Innovation: Leverage third‑party pharmaceutical logistics and e‑commerce to streamline distribution and reduce costs.
• Quality & efficiency: Maintain high product and service standards while optimizing supply‑chain performance.

• Revenue drivers: wholesale distribution to hospitals and clinics, retail pharmacy sales, online pharmacy orders, and sales of consumables and test reagents.
• Cost structure: procurement of pharmaceutical goods, logistics (including third‑party partners), retail operating expenses and online platform costs.
• Profit levers: scale in regional distribution, higher‑margin retail and proprietary brands, logistics efficiencies, and increased online sales penetration.

• Distribution network: earns margins by purchasing wholesale pharmaceuticals and selling to medical institutions and pharmacies.
• Retail & online sales: captures retail margins via physical stores and an integrated e‑commerce channel.
• Logistics & services: monetizes warehousing, cold‑chain and third‑party distribution services.
• Value‑added products: sales of higher‑margin consumables, test reagents and proprietary or exclusive product lines.

Guangxi LiuYao Group Co., Ltd (603368.SS): Mission and Values

• Customer-first ethos: ensure medicine accessibility and accurate pharmaceutical guidance.
• Compliance and quality: adherence to national drug safety, cold-chain and storage standards.
• Integrated service: seamless online-to-offline (O2O) continuity for consumers and medical institutions.
• Innovation: digital tools and inventory systems to optimize supply and delivery.

• Dual-channel distribution: combines e-commerce platforms and a network of physical pharmacies to reach both digital shoppers and walk-in customers.
• Diverse sourcing: procurement covers prescription drugs, OTC medicines, medical devices, traditional Chinese medicine preparations, and health supplements from domestic and multinational suppliers.
• Third-party logistics partnerships: contracts with regional 3PLs and national carriers for warehousing, cold-chain where necessary, and last-mile delivery to customers and clinics.
• E-commerce integration: proprietary and third-party online storefronts enable online ordering, telepharmacy support, appointment booking, and home delivery services.
• Technology and infrastructure: investment in warehouse management systems (WMS), point-of-sale (POS) integrations, and mobile/mini-program ordering to synchronize inventory across channels.
• Inventory management: centralized SKUs and demand forecasting to reduce stockouts, optimize turnover rates, and improve working capital efficiency.

• Retail pharmacy sales: prescription and OTC transactions through the company's physical outlets and e-pharmacy channels.
• Wholesale distribution: B2B supply to clinics, community health centers, and other pharmacies.
• Value-added services: in-store clinics, medication management, and paid delivery/consultation packages.
• Category diversification: higher-margin medical devices and supplements supplement core drug sales.

• Online: lower per-order margin but reduced overhead per transaction and higher reach; key for urban, younger demographics.
• Offline: higher-margin services, impulse purchases, and prescription fulfillment with pharmacist counseling.
• Wholesale: volume-driven, thinner margins but steady cash flow and customer stickiness with medical institutions.
• Logistics cost management: leveraging scale with 3PL partnerships to keep last-mile delivery costs aligned with average order values.

• Centralized procurement hub negotiates supplier contracts, enabling favorable purchase terms and quality control.
• WMS & POS integration provides near real-time visibility on stock levels across distribution centers and stores, enabling inter-store replenishment and automated reorder points.
• Cold-chain capabilities for temperature-sensitive pharmaceuticals managed via certified 3PL partners and monitored storage facilities.
• Safety stock and ABC classification for high-turn SKUs to minimize stockouts while reducing excess inventory.

• Expansion of retail footprint in tier-3/4 cities and township markets to capture underserved demand.
• Digital platform upgrades: mobile apps, mini-programs, and telepharmacy capabilities to grow online sales.
• Supply chain automation: investments in regional distribution centers and WMS to reduce lead times and logistics cost per order.
• M&A selectively to acquire local chains or wholesale networks and accelerate geographic coverage.

• Supplier relationships with major domestic pharmaceutical manufacturers for stable SKU supply and preferred pricing.
• 3PL and last-mile partners to scale delivery capability across Guangxi and neighboring provinces.
• Technology vendors for POS, WMS, and e-commerce integrations to support an omnichannel customer experience.

Guangxi LiuYao Group Co., Ltd (603368.SS): How It Works

• Procurement & supplier relationships: centralized buying from domestic pharmaceutical manufacturers and medical device suppliers to secure scale discounts and product variety.
• Wholesale distribution: supplying hospitals, clinics, community pharmacies and other institutional buyers through regional distribution centers.
• Retail pharmacy network: operating self‑owned retail stores and franchised outlets for direct consumer sales of OTC and prescription medicines, consumables and health products.
• Online pharmacy & e‑commerce: proprietary online storefronts and listings on major platforms; home delivery and telepharmacy services to capture growing digital demand.
• Third‑party logistics (3PL): cold chain and standard pharmaceutical distribution services offered to other healthcare companies, leveraging the company's warehousing and last‑mile delivery capabilities.
• Partnerships & channel collaborations: distribution agreements, joint promotions and service alliances with upstream manufacturers and downstream retail/medical partners.

• Product sales margin: primary income from mark‑ups on medicines, medical devices and consumables sold through wholesale and retail channels.
• Online transaction fees & delivery charges: commissions and delivery fees earned on e‑commerce orders plus fees for premium home‑delivery/fast‑fulfillment services.
• Retail store sales: direct consumer purchases in physical stores, with additional revenue from value‑added services such as medication counseling, health checks and loyalty programs.
• Logistics & service contracts: fee income from third‑party logistics services, warehousing and distribution contracts with other pharmaceutical firms and healthcare providers.
• Collaborative income: revenue sharing, promotional support fees and co‑development payments from strategic partnerships and supplier agreements.

• Scale purchasing lowers COGS: centralized procurement and large purchase volumes reduce unit costs and improve margins on wholesale and retail sales.
• Channel diversification: balancing offline store footprint with online pharmacies mitigates single‑channel risk and captures urban e‑commerce growth.
• Logistics integration: owning or tightly managing distribution centers and delivery networks reduces fulfillment costs, shortens lead times and enables paid logistics services to third parties.
• Regulatory & product mix: higher‑margin medical devices and consumables, plus branded OTC products, help lift blended margins compared with low‑margin generics.
• Cost structure: retail store operating costs (rent, payroll), logistics expenses and technology/platform investments are the main levers affecting net income.

• Scaling online penetration and omnichannel fulfillment to raise e‑commerce share and lower per‑order delivery costs.
• Expanding 3PL services regionally, targeting hospitals and manufacturers seeking outsourced distribution.
• Deepening supplier partnerships for exclusive SKUs or co‑branded products with higher margins.
• Optimizing store network (format mix, location rationalization) to improve same‑store profitability.

Guangxi LiuYao Group Co., Ltd (603368.SS): How It Makes Money

• Core revenue streams: wholesale distribution of prescription and OTC drugs, retail pharmacy sales, medical consumables and cold-chain logistics services.
• Value-add services: inventory financing, logistics management, supply-chain integration and IT-driven sales analytics for suppliers and healthcare institutions.
• Distribution approach: dual-channel model - commercial wholesale + direct retail/institutional distribution - boosting market reach and margin control.

• Scale advantages from being a top-50 distributor: purchasing leverage, supplier contracts and regional penetration.
• Margin expansion from direct retail and value-added logistics where pricing power and service fees are higher than pure wholesale.
• Tech investments that reduce working capital needs (faster turnover), lower logistics costs and enable higher SKU-level profitability.
• Stable analyst-backed growth expectations (4.5% revenue/earnings CAGR; EPS +4.3% CAGR) supporting incremental shareholder value.